The short version of Dihexa fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
{\displaystyle {\hat {H}}={\frac {{\hat {p}}_{x}^{2}+{\hat {p}}_{y}^{2}+{\hat {p}}_{z}^{2}}{2m}}+{\frac {\omega _{c}}{2}}({\hat {x}}{\hat {p}}_{y}-{\hat {y}}{\hat {p}}_{x})+{\frac {1}{2}}m\left({\frac {\omega _{1}}{2}}\right)^{2}({\hat {x}}^{2}+{\hat {y}}^{2})+{\frac {1}{2}}m\omega _{z}^{2}{\hat {z}}^{2}}
Known colloquially as "Laborit's drug", chlorpromazine was released onto the market in 1953 by Rhône-Poulenc and given the trade name Largactil, derived from large "broad" and acti* "activity". Deniker then visited America, where the publication of their work alerted the American psychiatric community that the new treatment might represent a real breakthrough. Heinz Lehmann of the Verdun Protestant Hospital in Montreal trialled it in seventy patients and also noted its striking effects, with patients' symptoms resolving after many years of unrelenting psychosis. By 1954, chlorpromazine was being used in the United States to treat schizophrenia, mania, psychomotor excitement, and other psychotic disorders. Rhône-Poulenc licensed chlorpromazine to Smith Kline & French (today's GlaxoSmithKline) in 1953. In 1955 it was approved in the United States for the treatment of emesis (vomiting). The effect of this drug in emptying psychiatric hospitals has been compared to that of penicillin on infectious diseases. The popularity of the drug fell in the late 1960s as newer drugs came on the scene. From chlorpromazine several other similar antipsychotics were developed, leading to the discovery of antidepressants. Chlorpromazine largely replaced electroconvulsive therapy, hydrotherapy, psychosurgery, and insulin shock therapy. By 1964, about fifty million people worldwide had taken it. Chlorpromazine, in widespread use for fifty years, remains a "benchmark" drug in the treatment of schizophrenia, an effective drug although not a perfect one.
=== September === 1 September The James Webb Space Telescope takes its first direct images of a planet beyond the Solar System. The exoplanet, HIP 65426 b, is revealed in different bands of infrared light. Neuroscientists report the discovery of the axo-ciliary synapse – communication between serotonergic axons and antenna-like primary cilia of CA1 pyramidal neurons that alters the neuron's epigenetic state in the nucleus. Scientists elaborate a need for an evidence-based reform of regulation of genetically modified crops (moving from regulation based on characteristics of the development-process to characteristics of the product) in a paywalled article. 2 September – A first spatiotemporal map reveals key insights about axolotl brain regeneration. 5 September – Researchers report the development of remote controlled cyborg cockroaches functional if moving to sunlight for recharging. 6 September – The U.S. Department of Agriculture approves a new purple tomato, genetically modified to alter its colour and enhance its nutritional quality. 7 September – A new malaria vaccine developed by the University of Oxford is shown to be ~80% effective at preventing the disease. 8 September – A study adds to the accumulating research indicating postexposure antiviral TIPs could be an effective countermeasure that reduces COVID-19 transmission. In September, India and China approve the two first nasal COVID-19 vaccines which may (as boosters) also reduce transmission (sterilizing immunity).
== V == Vagus nerve Cranial nerve X, responsible for parasympathetic control of the heart, lungs, and digestive tract. It also conveys sensory information from the viscera to the brainstem. Vasopressin Also known as antidiuretic hormone (ADH), it regulates water balance and blood pressure. In the brain, vasopressin influences social behavior and memory. Ventral A directional term meaning "toward the front" in the spinal cord or "toward the bottom" in the brain. Opposite of dorsal. Ventral horn The anterior portion of the spinal cord’s gray matter, containing motor neurons that project to skeletal muscles. Ventral stream A visual processing pathway ("what" pathway) that travels from the occipital lobe to the temporal lobe and is involved in object recognition and form representation. Ventral tegmental area (VTA) A midbrain structure containing dopaminergic neurons that project to the nucleus accumbens and prefrontal cortex, central to reward and motivation. Ventricles A set of interconnected cavities in the brain filled with cerebrospinal fluid (CSF), which cushions the brain and maintains intracranial pressure. Vestibular system The sensory system that contributes to balance, spatial orientation, and coordination of head and eye movements. Includes the semicircular canals and otolith organs. Vestibulo-ocular reflex (VOR) A reflex that stabilizes vision by producing eye movements in the opposite direction of head movement, allowing steady gaze.
=== Offices (Ämter) === Ämter ("offices" or "bureaus"): in some states, there is an administrative unit between the districts and the municipalities, called Ämter (singular Amt), Amtsgemeinden, Gemeindeverwaltungsverbände, Landgemeinden, Verbandsgemeinden, Verwaltungsgemeinschaften, or Kirchspiellandgemeinden.
Sources: en.wikipedia.org
However, Karachi-based K-Electric and Water and Power Development Authority (WAPDA) generate much of the electricity used in Pakistan and collect revenue nationwide. In 2023, Pakistan's installed electricity generation capacity was ~45,885 MWt. Pakistan produced 1,135 megawatts of renewable energy for the month of October 2016. Pakistan expects to produce 10,000 megawatts of renewable energy by 2025.
== Chemistry == Flunitrazepam is classed as a nitro-benzodiazepine. It is the fluorinated N-methyl derivative of nitrazepam. Other nitro-benzodiazepines include nitrazepam (the parent compound), nimetazepam (methylamino derivative) and clonazepam (2ʹ-chlorinated derivative). Flunitrazepam has a melting point of around 170 degrees Celsius.
Without separation coupling, the basic building blocks in MMS, which are similar in composition with the conventional laboratory counterpart, are sample inlet, ionization source, mass analyzers, detector, vacuum system, instrument control and data acquisition system. Three most important components in MMS contributing to miniaturization are mass analyzer, vacuum system and electronics control system. Reducing the size of any components is beneficial to the miniaturization. However, it is noticeable that minimizing the analyzer’s size can greatly enhance the miniaturization of the other components especially the vacuum system because the analyzer is the pressure deciding factor for MS analysis and pressure interface fabrication.
== History == Dihydroergotamine was synthesized by Albert Hofmann and Werner Stoll at Sandoz in 1943. It was first described in the scientific literature that same year. Dihydroergotamine was first approved for medical use under the brand name D.H.E. 45 in 1946. Dihydroergotamine is derived from ergot, a fungus that grows on rye and other grains.
=== June === 6 June MPs vote to suspend Margaret Ferrier, the MP for Rutherglen and Hamilton West, from the House of Commons for 30 days for breaching COVID-19 regulations, almost certainly triggering a by-election in her constituency. Kevin Stewart resigns as Minister for Transport after experiencing poor mental health. 7 June – Circular Economy Minister Lorna Slater confirms that Scotland's Deposit Return Scheme is to be delayed until at least October 2025, meaning it will launch at a similar time to similar projects in other parts of the UK. 8 June – Members of the National Union of Rail, Maritime and Transport Workers at ScotRail vote to accept a 5% pay increase for 2023–24. 11 June – Police Scotland arrest former First Minister Nicola Sturgeon as part of their ongoing investigation into the SNP's finances. She is subsequently released without charge. 12 June – First Minister Humza Yousaf tells BBC News he will not suspend Nicola Sturgeon from the SNP following her arrest. 13 June BMA Scotland announces that junior doctors have rejected a 14.5% pay offer from the Scottish Government and will stage a 72-hour strike from 12 to 15 July. Màiri McAllan, Scotland's Cabinet Secretary for Net Zero and Just Transition, is additionally appointed as Minister for Transport, replacing Kevin Stewart in the role. 14 June – Jo Farrell, the current Chief Constable of Durham Constabulary, is appointed as Police Scotland's first female Chief Constable; she will replace Sir Iain Livingstone, who retires in August.
Sources: en.wikipedia.org
== Other uses == C4, a variation of Command and control, meaning "Command, Control, Communications and Computers" C4, the monogram of Christian IV of Denmark, used in the city arms of Kristianstad, Sweden since 1622 C4 Extreme, a sports nutrition supplement product line by Cellucor, which includes C4 energy drinks
During examinations of the head and torso, this scattered radiation can spread throughout the body and is difficult to shield with radiation protective clothing. Fears that a lead apron will prevent radiation from leaving the body are unfounded, however, because lead absorbs radiation rather than scattering it. When preparing an orthopantomogram (OPG) for a dental overview radiograph, it is sometimes recommended not to wear a lead apron, as it does little to shield scattered radiation from the jaw area, but may hinder the rotation of the imaging device. However, according to the 2018 X-ray regulation, it is still mandatory to wear a lead apron when taking an OPG.
The conidia typically retain at least one adjacent spore-producing cell when broken away from the sporodochia, distinguishing A. roeperi conidiogenous structures from the less swollen, non-detachable conidiophores of A. xylebori; the original species description suggests this feature is meant to allow these units to snap off easily while X. crassiusculus is grazing upon the gallery. When within the beetle mycangium (a pocket in the insect cuticle for fungal dispersal), A. roeperi can be found as small, several-cell chains with crosswalls; this material is likely derived from chunks of mycelium scraped from the gallery walls and may thus constitute an arthrospore-like structure. Notably, this indicates that the conidia produced in the galleries are unlikely to act as the predominant dispersive forms of A. roeperi, and beetles instead transport fungi to new trees as disarticulated hyphae.
=== Metabolism === While other opioids in its class, such as codeine or oxycodone, are metabolized via CYP450 enzymes, hydromorphone is not. Hydromorphone is extensively metabolized in the liver to hydromorphone-3-glucuronide, which has no analgesic effects. As similarly seen with the morphine metabolite, morphine-3-glucuronide, a build-up in levels of hydromorphone-3-glucuronide may produce excitatory neurotoxic effects such as restlessness, myoclonus and hyperalgesia. Patients with compromised kidney function and older patients are at higher risk for metabolite accumulation.
Ceftolozane/tazobactam, sold under the brand name Zerbaxa, (Merck) is a fixed-dose combination antibiotic medication used for the treatment of complicated urinary tract infections and complicated intra-abdominal infections in adults. Ceftolozane is a cephalosporin antibiotic, developed for the treatment of infections with gram-negative bacteria that are resistant to conventional antibiotics. It was studied for urinary tract infections, intra-abdominal infections and ventilator-associated bacterial pneumonia. The most common side effects include nausea (feeling sick), headache, constipation, diarrhea and fever. Ceftolozane is a type of antibiotic called a cephalosporin, which belongs to the wider group of antibiotics called beta-lactams. It works by interfering with the production of molecules that bacteria need to build their protective cell walls. This causes weakness in the bacterial cell walls which then become prone to collapse, ultimately leading to the death of the bacteria. Tazobactam blocks the action of bacterial enzymes called beta-lactamases. These enzymes enable bacteria to break down beta-lactam antibiotics like ceftolozane, making the bacteria resistant to the antibiotic's action. By blocking the action of these enzymes, tazobactam allows ceftolozane to act against bacteria that would otherwise be resistant to ceftolozane. Ceftolozane is combined with the β-lactamase inhibitor tazobactam, which protects ceftolozane from degradation. It was approved for medical use in the United States in December 2014, and in the European Union in September 2015.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.